A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)

Clinical trial NCT07072169 · RECRUITING

Trial details

NCT number: NCT07072169
Sponsor: Ruijin Hospital
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

B-cell Non-Hodgkin Lymphoma

Start date: 2025-05-26
Primary completion: 2026-06-01
Enrollment: 56

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.